NVO Novo Nordisk A/S

$NVO Here’s why I think $100/share is coming. Wegovy Pill vs Foundayo — Global Approval & Launch Status One thing I think investors are overlooking is how large Novo’s international regulatory head start currently is in oral obesity. Wegovy pill — Novo Nordisk Approved / authorized: 🇺🇸 United States — FDA approved Dec. 2025; launched Jan. 5, 2026 🇦🇪 UAE — approved and launched June 2026 🇬🇧 United Kingdom — approved June 2026; launched early July 🇪🇺 European Union — European Commission authorization granted July 15, 2026, covering all 27 EU member states. Commercially available today in at least: 🇺🇸 U.S. 🇦🇪 UAE 🇬🇧 UK 🇩🇪 Germany — launched Sept. 1 and became the first EU country to commercially launch oral Wegovy. Novo has said more selected international launches are coming. Mexico has been discussed as an upcoming market, but I would not count it as commercially launched yet without a confirmed regulatory/launch notice. Regulatory footprint: Because one centralized EU authorization applies across the 27-member EU, Wegovy pill is now authorized across roughly 30 jurisdictions: 27 EU countries + U.S. + UK + UAE Commercial launch is occurring country by country. ⸻ Foundayo — Eli Lilly Approved: 🇺🇸 United States — FDA approved April 1, 2026; launched immediately afterward. 🇦🇪 UAE — approved April 2026 and now available. 🇲🇽 Mexico — approved for obesity and type 2 diabetes; Lilly said commercial launch would occur later in 2026. 🇸🇦 Saudi Arabia — approved Aug. 2; the Saudi regulator currently lists Foundayo with “Marketing Status: Marketed.” 🇬🇧 United Kingdom — approved Aug. 10 and commercially launched Aug. 24 through private prescription. European Union: ❌ Foundayo is NOT yet EU-approved. As recently as the September EMA meeting, orforglipron was still in the regulatory process at the “list of outstanding issues” stage. That means Lilly still needs to clear the CHMP process and receive European Commission authorization before it can broadly commercialize Foundayo across the EU. ⸻ Current comparison Wegovy pill ✅ U.S. ✅ UK ✅ UAE ✅ Entire EU regulatory authorization ✅ Germany already commercially launched ➡️ Additional international markets coming Foundayo ✅ U.S. ✅ UK ✅ UAE ✅ Saudi Arabia ✅ Mexico approved, launch pending/rolling out ❌ EU approval still pending ⸻ Why this matters The U.S. competition receives almost all the attention, but internationally Novo currently has a meaningful first-mover advantage. Wegovy pill is already authorized throughout the entire EU, while Lilly is still going through the EU regulatory process. That gives Novo an opportunity to establish: • doctors • patients • pharmacy inventory • payer relationships • brand recognition • recurring prescriptions before Foundayo enters many European markets. Novo does not need to wait for another EMA approval to enter France, Spain, Italy, Denmark, Sweden and other EU countries. The EU-wide authorization already exists; commercial launches now depend primarily on country-level pricing, access, distribution and Novo’s rollout decisions. Reuters confirmed on Sept. 30 that Wegovy pill was already available in the U.S., UK, Germany and UAE, with further international launches expected. So right now the global oral race is not simply: Wegovy vs Foundayo in America. It is also: How many countries can Novo establish Wegovy pill in before Lilly receives the regulatory approvals necessary to follow? That international head start could become strategically important if obesity pills evolve into a mass-market global therapy. My NVO thesis for 2028 is increasingly about global oral leadership, not necessarily retaking U.S. injectable leadership. Lilly may ultimately win the injectable obesity market, perhaps around 65–70/30, but Novo has an opportunity to reverse that relationship in oral obesity globally. Wegovy pill launched first, produced one of the strongest pharmaceutical launches in U.S. history, and Novo is now using its regulatory and manufacturing lead to expand internationally before Foundayo reaches many of those markets. If Novo can establish Wegovy oral as the incumbent global obesity pill, maintain a large injectable franchise, successfully commercialize CagriSema and return the company to sustainable double-digit growth, today’s ~9–10× earnings valuation could prove far too pessimistic. My personal 2028 scenario is approximately $100/share—not because Lilly fails, but because the obesity market becomes large enough for Lilly to win and Novo to win simultaneously. Data current through Oct. 5, 2026. This is factual/research commentary, not financial advice. Not financial advice, my personal opinions.

$NVO This is interesting, but bankruptcy is not likely. Let’s do some comparable: Look at Novo’s actual financial position. 2025 Novo Nordisk financials, approximately in USD: • Revenue: ~$46.4 billion • Operating profit: ~$19.2 billion • Net income: ~$15.4 billion • EBITDA: ~$22.4 billion • Operating margin: 41.3% • Net margin: 33.1% • Gross margin: 81% • ROIC: 39.3% • Net debt: ~$14.3 billion • Net debt/EBITDA: only ~0.64× Think about that for a moment. Novo generated more net profit in one year than its entire net-debt position. A company earning roughly $15 billion annually, with debt below one year’s EBITDA and operating margins above 40%, does not remotely resemble a typical bankruptcy candidate. And 2026 has not suddenly turned into a disaster. In Q2 2026 alone, Novo produced approximately: • Revenue: ~$11.8 billion • Adjusted operating profit: ~$5.0 billion • Net income: ~$3.2 billion • Adjusted operating margin: ~42.5% That’s roughly $55 million of adjusted operating profit every single day during the quarter. Novo also generated roughly $6.4 billion of free cash flow in the first half of 2026. This is not what financial distress looks like. ⸻ Novo is also one of the most profitable major pharmaceutical companies in the world. Approximate 2025 net margins: • Novo Nordisk: 33.1% • Eli Lilly: 31.7% • Johnson & Johnson: 28.5% • Merck: 28.1% • Novartis: 25.6% • Roche: ~22% • Sanofi: ~18% • Pfizer: ~12% Novo is not the largest pharma company by revenue, but its economics are elite. For approximately every $100 of sales, Novo earned around $33 in net profit. ⸻ The underlying franchises are enormous. Approximate 2025 sales: • Ozempic alone: ~$19.1 billion • Total diabetes business: ~$31.1 billion • Obesity care: ~$12.3 billion • Rare disease: ~$2.9 billion Ozempic by itself is a nearly $20 billion annual franchise. And Novo is not just a U.S. Wegovy company. Novo: • Treats roughly 46.5 million patients worldwide • Sells medicines in roughly 170 countries • Has tens of thousands of employees • Operates manufacturing across multiple continents • Remains one of the dominant global companies in diabetes and obesity ⸻ The balance sheet is another major problem for the bankruptcy argument. Novo had roughly: • $14.3 billion net debt • $22.4 billion EBITDA That’s only about 0.64× net debt/EBITDA. Novo also carries very strong investment-grade credit ratings: • S&P: AA • Moody’s: Aa3 Credit markets therefore currently view Novo as a very high-quality borrower, not a distressed company. Novo has also been able to issue long-term bonds extending decades into the future. That doesn’t make bankruptcy mathematically impossible. Nothing is impossible. But it tells you how far the current financial situation is from genuine insolvency. ⸻ Novo is also still spending aggressively because it has the financial capacity to do so. In 2025 Novo spent approximately: • ~$9 billion on property, plants and equipment plus roughly: • ~$4.5 billion on business-development/intangible investments So Novo was deploying roughly $13+ billion into manufacturing capacity and pharmaceutical assets while remaining enormously profitable. That’s very different from a company borrowing money simply to survive. ⸻ The company also still has multiple major growth assets. Novo’s franchise includes: • Wegovy injectable • Wegovy pill • Higher-dose Wegovy • Ozempic • Rybelsus • Awiqli once-weekly insulin • CagriSema • Zenagamtide/amycretin • Additional oral obesity drugs • Broader cardiometabolic and rare-disease programs The Wegovy pill itself became one of the largest pharmaceutical launches by prescription volume and has already generated millions of prescriptions. Again, you can debate whether Lilly’s products are better or whether Novo’s pipeline will succeed. But that’s a competitive-positioning argument, not a bankruptcy argument. ⸻ What would actually have to happen for Novo bankruptcy to become a serious discussion? You would likely need several disasters to happen simultaneously: 1. Semaglutide sales collapse globally. 2. Ozempic loses a massive portion of its business. 3. Wegovy collapses rather than simply loses some share. 4. Novo’s insulin franchise deteriorates severely. 5. International operations collapse. 6. Most next-generation pipeline programs fail. 7. Operating margins fall from around 40% toward zero or negative. 8. Free cash flow becomes persistently negative. 9. Debt increases dramatically. 10. Credit markets become unwilling to refinance the company. Compare that hypothetical scenario with reality today: ~$46 billion revenue ~$19 billion operating profit ~$15 billion net income ~$22 billion EBITDA ~$14 billion net debt ~33% net margin ~41% operating margin ~81% gross margin AA/Aa3 credit ratings ~46.5 million patients ~170 countries Those two pictures aren’t remotely similar. This is my personal analysis and opinion, not financial advice.

$NVO in case it was not clear how absolutely manipulated the Stockmarket is. The Last US institutional Upgrade was at March 2024 the price hit that year almost 150. Since then Revenue +52%, Net profit +50 % Stock price more than -70 % . Let that sink in. Those Experts explaining the unexplainable ,make it just more laughable.

$NVO Let me tell you exactly what's going to happen and what you guys are going to do. Slowly but surely, we'll approach the Q3 er report. Until then, the market will consolidate, and we'll reach earnings day somewhere between $38 and $44. Then the report drops and everyone is blown away by the massive beat (which shouldn't be a surprise, since the sales data already point to it). The stock suddenly takes off, climbing toward $55–60 within a matter of weeks. And that's when you guys start taking profits right in the middle of the rally, or, if that's your entry price, you immediately run for the exit the moment you're finally back at breakeven. Meanwhile, NVO will steadily march its way above $100, but you guys will be nowhere to be found. You'll have been out of the stock for ages. People, give this company 1–2 years and you'll witness something incredible. And it's not magic. It's simply the end of the massive sell-off and undervaluation, followed by a recovery in confidence.

$NVO Don’t sell a safe haven. People are going to be looking to get in. Let’s get the price up where it should be.

$NVO also just want to say it again, I’m not a course selling, I don’t sell anything to anyone in this community. I post personal opinions like. Everyone else. I do this for entertainment only. To be part of the community. Everything posted is free to view. I will never ask anyone’s email, subscription or payment. If you read it, be appreciated of it. If you are disrespectful, I will 100% block and you will never be able to see my posts again. Good luck enjoying all the boring posts. Additionally, I hold long bull position in novo.

$NVO Many people will be convinced that this means nothing and will open short positions on every bounce—after all, Novo *has* to drop to 35... but that will serve as fuel for further gains. There’s no one left to shake out after this sell-off; anyone who wanted or needed to sell has already done so. Now, an upward revision of forecasts in Q3 is the obvious next step—that’s coming in a month, and the market is positioning for it right now. This time, the blind hatred toward Novo will work to our advantage!

$NVO Just bought my third tranche: 775 at 38.39 USD at New York. And as I said before, wont touch them until minimum 100.

$NVO good rebound as treasury yields drop, rotation out of Ai and tech, and realization of how undervalued Novo is - then add in 1. High likelihood of earnings beat first week of November and raised forecasts and 2. Strong chance of positive FDA news any day over next 8-10 weeks - the setup could be for this to rocket back towards $50+

$NVO Even though this is currently beyond beaten down in the dumps, this is a HIGHLY PROFITABLE COMPANY that has real revenues, real earnings, and so the risk to reward ratio is HIGH! You do have to have real patience and guts to wait it out until Mr. Market realizes this is an opportunity of a lifetime! Well.. I for one, am waiting! Patiently!

$NVO Let’s hope we see a rotation into companies that actually make money and pay a dividend

The market may be underestimating $NVO’s obesity pipeline. Novo’s UBT251 delivered an impressive 19.7% weight loss in just 24 weeks, compared with 17.5% for Lilly’s retatrutide in a separate Phase 2 trial. Not head-to-head, but Novo has another serious contender. 💊

$NVO This should be trading $45-$50 this price is crazy if you look at most Pharma their PE’s range grom 18-40, this is extremely undervalued but given the current management and CEO the market has discounted the stock

$NVO Today’s stock market largely operates by American rules; Criticism of Novo’s CEO misses the bigger picture. The US was never going to accept long-term dependence on a Danish company in such an essential, enormous and rapidly growing healthcare market. An American alternative was inevitable. Novo investors underestimated how important this narrative is to powerful US financial and institutional interests—including those backing Lilly—and how far they are willing to push it. But narratives cannot override real-world supply and demand: numbers do not lie, and production capacity cannot be created by decree. At some point, maintaining this pressure at Novo’s current valuation may become too costly. Novo appears to understand this and is expanding into other high-volume markets, for example Asia—which increasingly represent the future of global demand.

Novo’s ($NVO) early Zenagamtide results look very promising! At week 36, weight loss reached 24.3%, vs. 20.9% for Lilly’s ($LLY) tirzepatide in a separate trial. Zenagamtide could potentially outperform tirzepatide, but head-to-head data are needed to confirm.

$NVO This is a change. Not many days where the Danes have really bought it up and challenged Wall Street’s pro LLY, anti NVO obsession. This is what I personally have been waiting for.

$NVO What is comical is that we have companies trading with PE’s of 300-400 that make no money and rise every day and we have a company like NVO that makes money with a PE under 10 and a 4.5 yield and gets ssold off every day, that’s Wall Street for you

$NVO The wegovy pill has great potential for constant growth on sales for a long, long time because of market expansion into emerging markets. Novos manufacturing capability will come in handy and is a moat when new products emerge faster than before because of AI driven research and development.

$NVO My interpretation based on the stock’s performance: Certain players—and by that I mean the Mafia—aren’t satisfied yet. They still need a few million more of our shares. Given the outlook, and based solely on the global “consumption”/use of semaglutide, Novo Nordisk won’t need any of its other products for the next 5 years. As for the patents expiring: It’s a non-issue. They’ll generate more revenue over the next 5–10 years than Apple did initially with its iPhone. I see the users every day—there are more and more of them, and they’re not going to stop using it. Prices will hit >100 in the next 6–12 months, or I’ll turn in my medical license. The current prices are absolutely fantastic. I’m even grateful to the Mafia for that.

$NVO Only clowns are covering today. Don't be a clown and don't short a company 80% from all time high.